Antibiotic-modifying activity of riachin, a non-cyanogenic cyanoglycoside extracted from Bauhinia pentandra

Pablo Antonio Maia de Farias1,3
Fernando Gomes Figueredo1,3
Aline Maria Brito Lucas1
Rafael Barbosa de Moura2
Henrique Douglas Melo Coutinho2
Tania Maria Sarmento da Silva4
Ana Luiza de Aguiar Rocha Martin2,3
Marta Maria de França Fonteles1

1Development and Technological Innovation in Medicines, Universidade Federal do Ceará – UFC, Fortaleza-CE, 2College of Biomedicine, Faculda Leão Sampaio-FLS, 3College of Pharmacy, Faculdade de Medicina, Estácio de Juazeiro do Norte-Estácio, Juazeiro do Norte-CE, 4Department of Molecular Sciences, Universidade Federal Rural de Pernambuco, Recife, PE, Brazil

Background: The search for new active compounds from the Brazilian flora has intensified in recent years, especially for new drugs with antibiotic potential. Accordingly, the aim of this study was to determine whether riachin has antibiotic activity in itself or is able to modulate the activity of conventional antibiotics.

Methods: A non-cyanogenic cyanoglycoside known as riachin was isolated from Bauhinia pentandra, and was tested alone and in combination with three antibiotics (clindamycin, amikacin, and gentamicin) against multiresistant bacterial strains (Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus).

Results: Riachin did not show significant antibiotic activity when tested alone against any strain (P>0.05). However, when combined with conventional antibiotics, it showed drug-modifying activity against strains of S. aureus exposed to clindamycin (P<0.001) as well as against P. aeruginosa exposed to amikacin (P<0.001). Although riachin did not show direct antibiotic activity, it had synergistic activity when combined with amikacin or clindamycin. The mechanism of action of this synergism is under investigation.

Conclusion: The results of this work demonstrate that some substances of natural origin can enhance the effectiveness of certain antibiotics, which means a substantial reduction in the drug dose required and possibly in consequential adverse events for patients.

Keywords: riachin, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus

Introduction
Infectious diseases of bacterial origin are a recurrent problem in public health, and have a substantial impact on morbidity and mortality in populations in general. Therefore, in recent years, the pharmaceutical industry has been prompted to develop new antibiotic drugs, in particular because of the emergence of microorganisms resistant to conventional drugs.1 This occurs because bacteria have the genetic capacity to acquire and transmit resistance to the antibacterial agents currently available. There are various reports on bacterial isolates that are known for being sensitive to routinely used drugs, but have now become resistant to other medications available on the market.2,3 Consequently, pharmaceutical companies are searching for new strategies to supply the market with new antibiotics. The most common strategies involve altering the molecular structures of existing drugs, with the aim of making them more effective or able to recover their lost activity due to the presence of bacterial resistance mechanisms.4 Accordingly, natural products such as those of plant origin have been identified as not only having antibacterial activity but also as being able to potentiate antibiotic activity.5,6

The Brazilian flora is very diverse, and still has a large variety of species not yet studied; each year, new substances are identified in nature, and many of these may...
have the potential to be developed as new drugs. Plants of Northeast Brazil under investigation include species of Bauhinia, among which Bauhinia forficata has been utilized by the people for many years, principally because of its hypoglycemic activity, a property reported back in the 1990s by various authors.7–9 Another species that has shown scientific relevance is Bauhinia pentandra, which has demonstrated antiulcer activity,10 and has an inhibitory effect on factor XIIa in the coagulation cascade.11,12

B. pentandra (Bong.) Vog. Ex Steud (Fabaceae) is known in Northeast Brazil as “mororo-de-espinho”, and can be found in the Caatinga region and in caatinga-cerrado transition forests. The stem bark is widely used as a depurative tonic and in the treatment of diabetes.13 Among the substances identified in the species of Bauhinia, are beta-sitosterol and kaempferol-3,7-dirhamnoside (kaempferitin).14 Investigation of the root bark of B. pentandra (Fabaceae) led to isolation and characterization of a new cyanoglycoside called riachin. This drug has demonstrated antioxidant potential in 1,1-Diphenyl-2-picrylhydrazyl (DPPH) and 2,2′-azino-bis-3-ethylbenzthiazoline-6-sulphonic acid (ABTS) tests, in addition to metal-chelating activity, including for ferrous (Fe²⁺) ions.15

The cyanoglycosides are widely known for their toxicity, but some have pharmacological activity, for example, an anti-allergic action,16 without toxic effects. However, the majority of cyanoglycosides in nature are cyanogenic, meaning they contain an alphanitrile group adjacent to a glycosidic bond, such that hydrolysis of these glycosides by glycosidases, followed by oxidation of the resultant cyano hydrin, releases the corresponding aldehyde or ketone and hydrocyanic acid.

Plants contain cyanogenic compounds are deemed not fit for animal or human consumption in their natural state, and can only be ingested if the cyanide has been eliminated by milling or heating.

Although riachin is a cyanoglycoside, the position of the cyano group is not next to the glycosidic bond of the molecule, so its hydrolysis does not result in the release of cyanide, which decreases its toxicity. Accordingly, riachin is found in a limited group of non-cyanogenic cyanoglycosides, such as simmondsin17 and laphoriside isolated from Lophira alata, a common plant in Africa,18 as well as the more recently isolated class of cyanoglycosides called chrothiosides, which have been demonstrated to have antagonistic activity against histamine.19 The basic structure of this class was defined20 and later characterized as a non-cyanogenic cyanoglycoside, but under specific conditions, it can release a small quantity of cyanide.21

Non-cyanogenic cyanoglycosides belong to a group of substances that are still little studied, but they appear to show different activities in various systems, including the immune and nervous systems, and have antibiotic activity.

The objective of this study was to investigate, using an in vitro model, the antibiotic and antibiotic-modifying activity of riachin, a cyanoglycoside extracted from B. pentandra (Bong.) Vog. Ex Steudas, and assess its potential as a therapeutic alternative for the treatment of bacterial infections, alone or in combination with other antibiotics, to reduce the utilization of drugs with more frequent adverse reactions.

**Materials and methods**

The molecular structure of riachin has been analyzed with support from the ChEMBL database, a strategic grant from the Wellcome Trust and the European Molecular Biology Laboratory (EMBL) for the field of chemogenomics. Access is free via the European Bioinformatics Institute (EBI, https://www.ebi.ac.uk/chembl/), which is part of the EMBL and responsible for financing. EMBL-EBI makes data freely available from life science experiments that cover the entire spectrum of molecular biology. The ChEMBL is an open database manually fed from periodicals concerning small molecules.22,23

A search for similar molecules (having a minimum of 80% structural similarity to riachin) yielded six substances (Table 1). The activities of these substances as reported in

### Table 1 Molecular characteristics of the six substances identified by the ChEMBL database with 80% or more molecular similarity to riachin

<table>
<thead>
<tr>
<th>ChEMBL ID</th>
<th>Synonymous</th>
<th>Similarity (%)</th>
<th>Apparent molecular weight</th>
<th>ALogP</th>
<th>PSA</th>
<th>HBA</th>
<th>HBD</th>
<th>QED weighted</th>
</tr>
</thead>
<tbody>
<tr>
<td>ChEMBL1967788</td>
<td>SIDS71895</td>
<td>100</td>
<td>329.30</td>
<td>−2.51</td>
<td>163.63</td>
<td>9</td>
<td>6</td>
<td>0.31</td>
</tr>
<tr>
<td>ChEMBL1817899</td>
<td>Griffonin</td>
<td>100</td>
<td>329.30</td>
<td>−2.51</td>
<td>163.63</td>
<td>9</td>
<td>6</td>
<td>0.31</td>
</tr>
<tr>
<td>ChEMBL2268556</td>
<td>No synonyms</td>
<td>89.09</td>
<td>375.37</td>
<td>−2.6</td>
<td>161.86</td>
<td>10</td>
<td>5</td>
<td>0.32</td>
</tr>
<tr>
<td>ChEMBL1997657</td>
<td>SIDS44912</td>
<td>89.09</td>
<td>375.37</td>
<td>−2.6</td>
<td>161.86</td>
<td>10</td>
<td>5</td>
<td>0.32</td>
</tr>
<tr>
<td>ChEMBL1505416</td>
<td>SIDS22401404</td>
<td>89.09</td>
<td>375.37</td>
<td>−2.6</td>
<td>161.86</td>
<td>10</td>
<td>5</td>
<td>0.32</td>
</tr>
<tr>
<td>ChEMBL2268555</td>
<td>No synonyms</td>
<td>80.57</td>
<td>551.54</td>
<td>−0.35</td>
<td>197.39</td>
<td>13</td>
<td>5</td>
<td>0.14</td>
</tr>
</tbody>
</table>

**Abbreviations:** EMBL, European Molecular Biology Laboratory; ALogP, solubility octanol/water; PSA, polar surface area; HBA, hydrogen bond acceptor; HBD, hydrogen bond donor; QED, quantitative estimation of drug-likeness.

Drug Design, Development and Therapy 2015:9

3068 submit your manuscript | www.dovepress.com

Dovepress
the publications (Table 2) were considered to define the research procedures. Considering the evidence for antimicrobial activity of similar molecules, it was decided to investigate riachin as an antimicrobial agent or a modulator of antimicrobial activity.

### Bacteria

The bacterial strains utilized were *Escherichia coli*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* with the resistance profiles identified in Table 3. All strains were maintained on heart infusion agar (Difco Laboratories Ltd, West Molesey, UK). Before the assays, the strains were grown for 18 hours at 37°C in brain heart infusion broth (Difco Laboratories Ltd). All bacteria used in this work were previously reported as having the existence of efflux pumps sensitive to phenothiazines.\(^{24,25}\)

### Drugs

Gentamicin, amikacin, and clindamycin were obtained from Sigma Chemical Co (St Louis, MO, USA). The solutions were prepared according to the recommendations of the National Committee for Clinical Laboratory Standards.\(^{26}\) First, 1.2 kg of *B. pentandra* (Bong.) Vog. ex Steud. (Fabaceae) powdered root bark were extracted with ethanol in a Soxhlet apparatus at the Molecular Sciences Laboratory, Universidade Federal Rural de Pernambuco. The extract was concentrated under vacuum in a rotary evaporator. After being allowed to stand in the refrigerator, the crude residue had the appearance of a light brown precipitate (2.46%) and was identified by spectrophotometric methods as the cyanoglycoside riachin (Figure 1).\(^{13}\)

### Determination of MIC and modulation of antibiotic activity

The minimal inhibitory concentration (MIC) was determined by the broth microdilution assay using an inoculum of 100 μL for each strain suspended in brain heart infusion broth with a concentration of 10\(^6\) colony-forming units/mL in 96-well microtiter plates, with two-fold serial dilutions. Next, 100 μL of riachin were added to each well, where the final concentrations were in the range of 8–512 μg/mL. For the controls, the standard antibiotics (amikacin, gentamicin, and clindamycin) were used at final concentrations of 8–512 μg/mL. The plates were incubated at 35°C for 24 hours, after which growth was assessed using the resazurin assay. MIC was determined as the lowest concentration that inhibited bacterial growth.

To evaluate the ability of riachin to modify the action of the antibiotics, the MICs of gentamicin and amikacin (aminoglycosides) and clindamycin (lincosamide) were determined in the presence and absence of riachin in sterile microplates. The antibiotics were evaluated at concentrations of 2.88–2,500 μg/mL. All antibiotics tested were obtained from Sigma-Aldrich.

Riachin was dissolved in 10% brain heart infusion broth at a subinhibitory concentration, which was determined by

### Table 2 Activity of molecules similar to riachin identified by ChEMBL

<table>
<thead>
<tr>
<th>ChEMBL ID</th>
<th>Synonymous</th>
<th>Reported activity</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>ChEMBL1967788</td>
<td>SID571895</td>
<td>Virtual testing (bacteria and yeast)</td>
<td>No related references</td>
</tr>
<tr>
<td>ChEMBL1817899</td>
<td>Griffonin</td>
<td>Antimicrobial (bacteria and yeast)</td>
<td>Mazimba et al(^{46})</td>
</tr>
<tr>
<td>ChEMBL2268556</td>
<td>No synonyms</td>
<td>Antifeedant, antifungal, and insecticide</td>
<td>Abbassy et al(^{47})</td>
</tr>
<tr>
<td>ChEMBL1997657</td>
<td>SID444912</td>
<td>Virtual testing (bacteria and yeast)</td>
<td>No related references</td>
</tr>
<tr>
<td>ChEMBL1505416</td>
<td>SID22401404</td>
<td>Antimicrobial (bacteria and yeast)</td>
<td>Mazimba et al(^{46})</td>
</tr>
<tr>
<td>ChEMBL2268555</td>
<td>No synonyms</td>
<td>Antifeedant, antifungal, and insecticide</td>
<td>Abbassy et al(^{47})</td>
</tr>
</tbody>
</table>

**Abbreviation:** EMBL, European Molecular Biology Laboratory.

### Table 3 Origin of bacterial strains and antibiotic resistance profile

<table>
<thead>
<tr>
<th>Bacteria</th>
<th>Origin</th>
<th>Resistance profile</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Escherichia coli</em> 27</td>
<td>Urine culture</td>
<td>Cefadroxil, cephalixin, cefaclor, cefepime, ceftriaxone, ampicillin-sulbactam</td>
</tr>
<tr>
<td><em>Escherichia coli</em> ATCC 25922</td>
<td>Not available</td>
<td>Not available</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em> 10</td>
<td>Rectal swab</td>
<td>Cefadroxil, cephalixin, cefaclor, oxacillin, penicillin, ampicillin, amoxicillin,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>moxifloxacin, ciprofloxacin, levofloxacin, ampicillin-sulbactam, amoxicillin-clavulanic acid, erythromycin, clarihromycin, azithromycin, clindamycin</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em> ATCC 25923</td>
<td>Not available</td>
<td>Not available</td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em> 03</td>
<td>Rectal swab</td>
<td>Cefepime, ceftazidime, ciprofloxacin, levofloxacin, meropenem, imipenem, and pipacillin-tazobactam</td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em> ATCC 25853</td>
<td>Not available</td>
<td>Not available</td>
</tr>
</tbody>
</table>
evaluation of its MIC, where the compound was diluted to an eight-fold reduced MIC (MIC/8). Antibiotic solutions were prepared by addition of sterile distilled water at double the concentration (5,000 μg/mL) in relation to the initial concentration defined and volumes of 100 μL diluted serially 1:1 in 10% brain heart infusion broth. Next, 100 μL of culture containing a bacterial suspension diluted 1:10 were added to each well. The same controls utilized in the evaluation of MIC for the sample were utilized for modulation.

The plates were incubated at 35°C for 24 hours, after which growth was measured by the resazurin assay. The antibacterial assay was performed in triplicate and the results were expressed as the mean of replicates.

Statistical analysis
Statistical analysis of the data was done using the GraphPad Prism® version 4.0 for Windows® software (GraphPad Software, San Diego, CA, USA). Data showing a parametric distribution were evaluated by analysis of variance. All data are shown as the mean ± standard error of the mean, and the critical level considered to reject the null hypothesis was 0.05 (P<0.05).

Results and discussion
The MIC of the test compound against the standard bacterial strains (E. coli ATCC 25922, S. aureus ATCC 25923, and P. aeruginosa ATCC 25853) showed the same result, ie, an MIC ≥1,024 μg/mL, with the exception of the sample against E. coli 25922, which had an MIC of 128 μg/mL. No clinically relevant activity was demonstrated, according to the limits established by the protocol. A pilot assay utilizing only dimethyl sulfoxide was performed, in which no antibiotic activity or antibiotic-modifying activity was observed, indicating that it had no influence at the concentration utilized (1.0%).

Figure 2 shows the MICs for the aminoglycosides and for clindamycin in the presence and absence of riachin (C_{14}H_{19}NO_8) at an MIC/8 concentration of 128 μg/mL. Thus, a significant synergistic effect (P<0.001) was seen against P. aeruginosa when amikacin was combined with the test compound and against S. aureus with the combination of riachin and clindamycin. The other results were not statistically significant (P>0.05).

Other studies using natural products or active substances from plants with antibiotic activity have obtained satisfactory results. These results are in agreement with other reports in the literature showing that combinations of natural products and antibiotics can reduce antibiotic resistance.
Few studies of *B. pentandra* have been published, and none have investigated the activity of the plant or its components against microorganisms. Other species of *Bauhinia* have shown some antibiotic activity,\(^3^0\) the most closely related being *Bauhinia tomentosa*, *B. vahlii*,\(^3^1\) *B. kockiana*,\(^3^2\) and *B. purpurea* L.\(^3^3\) However, the literature is still scarce with regard to the activity of plants of this genus against microorganisms. Since riachin can be isolated from the root bark of *B. pentandra* in good quantity (2.46%),\(^1^5\) it can be readily obtained for studies of its antibiotic activity.

Since the 1960s when the aminoglycosides were first introduced to the market, a number of infections caused by Gram-negative bacteria have been able to be treated more effectively, but at the expense of side effects, in particular nephrotoxicity\(^3^4,3^5\) and ototoxicity.\(^3^6-3^8\) The main adverse effects of clindamycin are gastrointestinal disturbance, which can manifest in the form of pseudomembranous colitis,\(^3^9\) and severe diarrhea. These side effects are relevant factors to be considered when treating patient with these agents. Thus, combination of riachin with amikacin or clindamycin could be an alternative to minimize the side effects of these antibiotics, since their combination leads to a synergistic effect and significant reduction in MIC, meaning that the dose needed for therapeutic success can be lowered.

The principal drug resistance mechanisms of bacteria involve modifications in the target bond in the ribosome, the efflux pump, or enzymatic inactivation of the drug.\(^4^0\) Clindamycin is often used in skin infections, particularly when there is resistance to penicillins.\(^4^1\)

The possible difference in activity of riachin against the *P. aeruginosa* strain when combined with amikacin and gentamicin is probably due to the structural differences in these aminoglycosides; both are hydrophilic molecules formed by an aminocyclitol ring connected to one or more amino sugars through a glycosidic bond. In most of the drugs with these characteristics and which are clinically useful – the aminocyclitol group is 2-deoxy-streptamine, which can be substituted at position 4 and 5, or 4 and 6,\(^4^2\) so being able to influence the the polarity, solubility, and consequently, the absorption of these drugs.

Our results are consistent with those found in the literature,\(^4^3\) and demonstrate that *E. coli* strains are more resistant to the action of natural products, such as extracts and essential oils.\(^4^4\) This could be due to the presence of other resistance mechanisms, including the efflux pump, production of enzymes that cleave the β-lactam ring (β-lactamases), and changes in penicillin-binding proteins.\(^4^5,4^6\)

**Conclusion**

The use of antibiotics is routine and necessary in clinical practice, but development of resistance makes it difficult to achieve the desired results in many patients, even in patients with low risk of severe adverse reactions for some drug classes, particularly the aminoglycosides. Accordingly, the activity of amikacin against *P. aeruginosa* and the activity of clindamycin against *S. aureus* could be potentiated if these antibiotics were combined with riachin. Due to the high polarity of riachin, this substance is likely to interact with efflux pumps in bacteria; tests are being developed to investigate this possibility using specific bacterial strains with defined and super-expression of efflux pumps. Further studies should be conducted, in particular studies of new combinations containing this natural drug and other bacterial strains. This compound may have a role as an adjuvant in some pharmaceutical formulations used to treat infection.

**Disclosure**

The authors report no conflicts of interest in this work. The authors alone are responsible for the content and writing of the paper.

**References**


